Chesnara's latest filings are director and PDMR shareholding notices dated 22 October 2026. The most recent financial update remains its half-year report of 25 August, which showed sharply higher Capital generation after an acquisition.

What happened

There is no new trading statement today. The two 22 October notices follow a grant of Options and PDMR dealing notice on 12 October, and further director shareholding notices on 26 August, 9, 11 and 29 September. A holdings notice was also filed on 10 September.

The contents of those dealing notices were not read for this article, so it does not say whether they involved purchases, sales or awards, or draw any conclusion from them. Their frequency simply marks the most recent regulatory activity.

The half-year position

According to an AI-generated summary from available data, operating capital generation rose 79% to £96m in the first half of 2026. Adjusted operating profit climbed 46% to £31m. These figures have not been checked against the full report, which was not on the page read.

Assets under administration increased 38% to £21bn, largely because of the Acquisition of Chesnara Life UK. The summary put the Solvency coverage ratio at 185%, which it described as comfortably above the group's operating range.

The Interim Dividend rose 6% to 8.16p per share, although payment and record dates were not stated.

A further acquisition is pending. The proposed purchase of Scottish Widows Europe SA was described as on track for completion around the end of 2026, and it is expected to add €250m of lifetime cash generation. A week after the half-year report, on 1 September, the company issued a non-regulatory item headed "Acquisitions show immediate benefits".

Why it matters for investors

Chesnara, ticker LSE:CSN, is a constituent of the FTSE All-Share index, and it operates in the insurance sector. Its Business model is built around acquiring and running life and pension books, and the half-year numbers show how much of its growth depends on those deals.

As analysis, the 79% rise in capital generation far outpaced the 6% dividend increase. The summary does not separate one-off effects of the acquisition from recurring gains, so the rise cannot be read as an underlying growth rate. (LSE:CSN)

The Scottish Widows Europe transaction is the next piece. A Solvency Ratio of 185% gives some context for capacity, although the summary does not say what the ratio would be after the deal completes.

How the shares have performed

Ticker.app showed 345.00p, up 2.50p, on a page last updated on 29 October 2026. It gave a 52-week range of 266.50p, set on 18 November 2025, to 377.50p on 1 September 2026, the date of the acquisitions item.

The one-month move shown was a fall of 3.9%. On this newsdesk's calculation, the price stood about 8.6% below the 52-week high and about 29% above the low. A price for 3 November could not be retrieved.

What to watch next

Completion of the Scottish Widows Europe acquisition, expected around the end of 2026, is the main scheduled event that has been identified. Investors will also look for what the deal adds to cash generation in practice, set against the €250m lifetime estimate.

No forthcoming results date was retrieved. Filings on provide the record of any further director dealings, and the next total voting rights notice would normally be the following routine item.